Study of a drug for sleepiness in Prader-Willi syndrome
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism, Mental health clinical trials.
This trial tests a medication called pitolisant to see if it helps reduce excessive daytime sleepiness in people with Prader-Willi syndrome. You or your loved one may be able to join if they have a confirmed diagnosis and a caregiver who can regularly help with study tasks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic diagnosis of Prader-Willi syndrome.
- You must experience significant sleepiness during the day.
- You need a parent or caregiver who is willing and able to assist with study assessments throughout the trial.
- Sleep apnea, if present, must be well controlled.
- You cannot have another sleep disorder causing your sleepiness, and you cannot be in another research study involving an experimental drug, device, or behavior treatment within the last 30 days or 5 half-lives.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication, pitolisant, in people with Prader-Willi syndrome who have already been in a pitolisant study. It aims to see if continuing treatment is safe and effective.
This trial tests an investigational drug called CSTI-500 for people with Prader-Willi syndrome who are in the hyperphagia (constant hunger) phase. It aims to see if the drug can improve behavior and reduce overeating. You and your caregiver will need to visit the clinic regularly and answer questions about symptoms.
This study tests an experimental drug called BMB-101 to see if it can help reduce the constant hunger (hyperphagia) that is common in Prader-Willi syndrome. The trial will check how safe and effective the drug is, and if it works, it may offer a new treatment option.
This trial tests a new medication, HBS-301, in people with idiopathic hypersomnia (a condition causing excessive sleepiness without clear cause). It aims to see if the drug improves wakefulness and is safe.
This study tests a new medicine, HBS-301, for people with narcolepsy type 1 or type 2 who still have excessive daytime sleepiness. If you take other medications for sleepiness or mood, they must be stable for at least 3 months, and you cannot take some as-needed sleepiness medicines.
This study tests whether a new medication called samelisant can reduce extreme daytime sleepiness and sudden muscle weakness (cataplexy) in people with narcolepsy. If it works, it could offer a new treatment option for managing this sleep disorder.
Hear when a new Prader-Willi Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.